PCR London Valves 2024

24 Nov 2024

TAVI

Rendez-vous with Myval THV series and Landmark RCT subset analysis

Sponsored by Meril Life

Discussants: I. J. Amat-Santos, P. Freeman, R. S. Rao, S. Haussig

Spokesperson: A. Baumbach

SHOW MORE

Summary

Discover this interactive session during which the audience learns about and discusses the novel Myval THV Series, a series of valves featuring intermediate and XL sizes. They also discuss the results of the pivotal LANDMARK randomized controlled trial and its relevance in clinical practice.

Learning Objectives

To learn about the novel Myval THV series, its key features, procedural and clinical benefits from the experts
To know more about the pivotal Landmark randomised controlled trial and its relevance in clinical practice
To discover clincal relevance of Intermediate and XL sizes in addressing large clinical unmet needs
To understand the strong relation between foreshortening and accurate deployment of transcatheter heart valve

Prof. Andreas Baumbach

Speaker

Welcome and session objectives

Download presentation

Speaker

Myval THV series design philosophy - Sizing, frame design and its impact on foreshortening, precise positioning, leading to acurate deployment

Download presentation

Ignacio J Amat-Santos

Speaker

I. J. Amat-Santos

Landmark randomised controlled trial - Key findings and clinical concepts

Download presentation

Speaker

Matching prosthesis to patient - Clinical and practical relevance of intermediate sizes

Download presentation

Dr. Nicolo Piazza

Speaker

XL size relevance not as trivial as it seems - Sizing considerations

Download presentation

Dr. Rao Ravinder Singh

Speaker

Relation between THV foreshortening and accurate deployment - The Pro effect

Download presentation